Last but not least, our findings provide a rationale for using p300 and GATA6 expression status to further stratify patient selection in RNF43-mutant pancreatic cancers to maximize the clinical efficacy of Wnt inhibitors. This evidence concerns the gene RNF43 and familial pancreatic carcinoma.